A Multicentre Feasibility Randomized Study of Anti-PD-L1 Durvalumab (MEDI4736) With or Without Anti-CTLA-4 Tremelimumab in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma, Treated With a First-line Neo-adjuvant Strategy

Trial Profile

A Multicentre Feasibility Randomized Study of Anti-PD-L1 Durvalumab (MEDI4736) With or Without Anti-CTLA-4 Tremelimumab in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma, Treated With a First-line Neo-adjuvant Strategy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Acronyms INeOV
  • Sponsors ARCAGY/GINECO Group
  • Most Recent Events

    • 23 Oct 2017 Planned primary completion date changed from 2 Sep 2017 to 1 Sep 2019.
    • 23 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 16 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top